| Not Yet Recruiting | Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients NCT07366658 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 |
| Recruiting | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) NCT07480213 | Beijing Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | Anlotinib in Cross-line Treatment of NSCLC and SCLC NCT07400575 | Henan Cancer Hospital | — |
| Not Yet Recruiting | A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consol NCT07358676 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer NCT07308379 | Fudan University | — |
| Recruiting | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With NCT07413042 | Peking University Cancer Hospital & Institute | Phase 1 |
| Not Yet Recruiting | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing NCT07141771 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Recruiting | A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors NCT07321574 | Shanghai AB PharmaTech Ltd. | Phase 2 |
| Not Yet Recruiting | A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression NCT07289048 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC NCT07110103 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy NCT07141264 | Tang-Du Hospital | Phase 2 |
| Recruiting | A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemothe NCT06812260 | Shanghai Henlius Biotech | Phase 2 |
| Recruiting | 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer NCT07508852 | Peking University First Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherap NCT06768307 | Peking University Cancer Hospital & Institute | Phase 2 |
| Not Yet Recruiting | Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia NCT06793228 | Henan Cancer Hospital | Phase 2 |
| Not Yet Recruiting | A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung NCT06620796 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Recruiting | Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC NCT06477523 | Sichuan University | Phase 1 / Phase 2 |
| Unknown | A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer NCT06267170 | Henan Cancer Hospital | — |
| Recruiting | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metasta NCT06243003 | Fudan University | Phase 1 / Phase 2 |
| Recruiting | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC NCT05718323 | ETOP IBCSG Partners Foundation | Phase 2 |
| Recruiting | Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC NCT07136285 | Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) NCT05623319 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Active Not Recruiting | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC NCT05595460 | RayzeBio, Inc. | Phase 1 |
| Unknown | TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors NCT05544149 | Zhejiang Cancer Hospital | Phase 2 |
| Unknown | Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer NCT05507593 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 |
| Completed | A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer NCT05505825 | Akeso | Phase 1 / Phase 2 |
| Completed | Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance NCT05933863 | Peking University Cancer Hospital & Institute | — |
| Unknown | Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer NCT05299255 | Henan Cancer Hospital | Phase 2 |
| Completed | Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer NCT04660097 | Henan Cancer Hospital | Phase 2 |
| Completed | Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC NCT05116007 | Akeso | Phase 1 |
| Recruiting | Lung Cancer Registry NCT04654364 | Arbeitsgemeinschaft medikamentoese Tumortherapie | — |
| Completed | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide NCT04221529 | AIO-Studien-gGmbH | Phase 2 |
| Unknown | Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lun NCT04731909 | Third Military Medical University | N/A |